Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton’s tyrosine kinase expression levels
Abstract Historically, CLL prognostication relied on disease burden, reflected in clinical stage. Later, chromosome abnormalities and genomics suggested several CLL subtypes which were aligned with response to therapy. Gene expression profiling data identified pathways associated with CLL progressio...
Saved in:
| Main Authors: | Gorkem Kismali, Ganiraju Manyam, Nitin Jain, Cristina Ivan, Betty Lamothe, Mary L. Ayres, LaKesla R. Iles, William G. Wierda, Varsha Gandhi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-12-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-024-01196-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia
by: Daniel Medina-Gil, et al.
Published: (2025-03-01) -
Cost impact of Bruton’s tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia
by: Adam S Kittai, et al.
Published: (2025-01-01) -
Bruton’s Tyrosine Kinase: A Double-Edged Sword in Cancer and Aging
by: Zahraa Qusairy, et al.
Published: (2025-05-01) -
The Potential Therapeutic Role of Bruton Tyrosine Kinase Inhibition in Neurodegenerative Diseases
by: Francesco D’Egidio, et al.
Published: (2025-07-01) -
The role of microglia in multiple sclerosis: implications for treatment with Bruton’s tyrosine kinase inhibitors
by: Patrick Vermersch, et al.
Published: (2025-05-01)